NDA 214518 · Siga Technologies
Tpoxx
Tecovirimat · Intravenous · Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor
OrphanLast checked: Nov 19, 2026Latest source record: Jun 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
May 18, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
5 Phase 3, 0 recruiting
FAERS reports
104
50 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 31, 2025.
TPOXX is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg. ( 1.1 ) Limitations of Use: The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. ( 1.2 ) TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models. ( 1.2 ) 1.1 Treatment of Human Smallpox Disease TPOXX ® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 3 kg. 1.2 Limitations of Use The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical [see Clinical Studies ( 14 )] . TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models.
Mechanism: Tecovirimat is an antiviral drug against variola (smallpox) virus [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TPOXX · TECOVIRIMAT 200MG/20ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tecovirimat" as an intervention, any sponsor and status, largest first.
- Study of Tecovirimat for Human Mpox VirusPivotal-lookingTerminated
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05534984 · 719 participants · Start Sep 8, 2022 · Primary completion Oct 23, 2024
Drug: Tecovirimat Oral Capsule; Placebo for Tecovirimat and 1 more · For: MPOX
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 54 sites in all
- Tecovirimat for Treatment of Monkeypox VirusPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05559099 · 597 participants · Start Oct 10, 2022 · Primary completion Sep 3, 2024
Drug: Tecovirimat Oral Capsule; Placebo · For: Monkeypox
Sites: Kole, Democratic Republic of the Congo; Tunda, Democratic Republic of the Congo
- Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus DiseasePivotal-lookingActive, not recruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT05597735 · 480 participants (planned) · Start Mar 3, 2023 · Primary completion Sep 30, 2026
Drug: Tecovirimat; Placebo · For: Monkeypox; Mpox
Sites: Buenos Aires, Argentina; Belo Horizonte, Brazil; Rio de Janeiro, Brazil · 12 sites in all
- Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysPivotal-lookingCompleted
SIGA TechnologiesIndustry
NCT04971109 · 467 participants · Start Mar 29, 2022 · Primary completion May 12, 2023
Drug: TPOXX · For: Smallpox
Sites: Miami, Florida; Orlando, Florida; Omaha, Nebraska · 9 sites in all
- A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatPivotal-lookingCompleted
SIGA TechnologiesIndustry
NCT02474589 · 449 participants · Start Jun 19, 2015 · Primary completion Aug 24, 2016
Drug: tecovirimat · For: Smallpox
Sites: Mobile, Alabama; Redding, California; San Diego, California · 11 sites in all
- European Trial Into Mpox InfectionPivotal-lookingStatus unknown
Miquel EkkelenkampAcademic, hospital or other
NCT06156566 · 150 participants (planned) · Start Aug 9, 2024 · Primary completion Dec 2025
Drug: Tecovirimat Oral Capsule; Placebo · For: Monkeypox
Sites: Antwerp, Belgium; Brussels, Belgium; Paris, France · 12 sites in all
- Tecovirimat in Non-hospitalized Patients With MonkeypoxPivotal-lookingSuspended
Marina KleinAcademic, hospital or other
NCT05534165 · 120 participants (planned) · Start Aug 14, 2023 · Primary completion Mar 13, 2025
Drug: Tecovirimat; Placebo · For: Monkeypox
Sites: Vancouver, Canada; Toronto, Canada · 3 sites in all
- Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246Pivotal-lookingCompleted
SIGA TechnologiesIndustry
NCT00907803 · 107 participants · Start Jun 2009 · Primary completion Jan 2010
Drug: ST-246 400 mg; ST-246 600 mg and 1 more · For: Orthopoxviral Disease
Sites: Santa Ana, California; Orlando, Florida; Honolulu, Hawaii
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug resistance19
- headache14
- nausea14
- fatigue12
- diarrhoea10
- acute kidney injury6
- alanine aminotransferase increased6
- decreased appetite5
- off label use5
- abdominal pain4
- dizziness4
- drug ineffective4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 10 |
| 2023 | 42 |
| 2024 | 35 |
| 2025 | 7 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.
Ali R, Alonga J, Biampata JL, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Multicenter Study
- Therapeutics for treating mpox in humans.
Fox T, Gould S, Princy N, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Effectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.
Shabil M, Khatib MN, Ballal S, et al. · J Med Virol 2024 · Systematic Review
- Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis.
Sanchez Clemente N, Coles C, Paixao ES, et al. · Lancet Glob Health 2024 · Meta-Analysis, Systematic Review
- Mpox vaccination and treatment: a systematic review.
Eslami A, Alimoghadam S, Khoshravesh S, et al. · J Chemother 2024 · Systematic Review
- Prevention and Treatment of Monkeypox: A Systematic Review of Preclinical Studies.
Sudarmaji N, Kifli N, Hermansyah A, et al. · Viruses 2022 · Systematic Review
Sponsor: Siga Technologies
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.